Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets

Article summary

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.